A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
SN BioScience
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Actuate Therapeutics Inc.
Gilead Sciences
Western Regional Medical Center
Western Regional Medical Center
Northwestern University
National Cancer Institute (NCI)